Ikeda Y, Kikuchi M, Toyama K, Watanabe K, Ando Y
Thromb Haemost. 1981 Apr 30;45(2):158-61.
The effects of verapamil, a coronary vasodilator, on platelet functions was studied. Platelet aggregation induced by ADP, epinephrine or collagen was inhibited by verapamil in vitro. Calcium ionophore A23187-induced platelet aggregation was also inhibited by verapamil in a concentration dependent manner. In washed platelets, verapamil caused a dose-dependent inhibition of serotonin release induced either by thrombin or A23187 in the absence of extracellular calcium. Addition of 1 mM CaCl2 with A23187 or thrombin partially overcame this inhibition. Addition of 1 mM CaCl2 in the absence of verapamil had no effect on thrombin- or A23187-induced secretion. When verapamil was administered to the healthy volunteers at the dosage commonly used, inhibition of platelet aggregation was observed 2 hrs after the drug ingestion. It is of great interest that verapamil potentiated the anti-aggregating activity of prostacyclin in vitro. Our results may suggest a potential role for verapamil in the treatment of thrombotic disorders.
研究了冠状动脉扩张剂维拉帕米对血小板功能的影响。在体外,维拉帕米可抑制由二磷酸腺苷(ADP)、肾上腺素或胶原诱导的血小板聚集。钙离子载体A23187诱导的血小板聚集也被维拉帕米以浓度依赖的方式抑制。在洗涤过的血小板中,在无细胞外钙的情况下,维拉帕米对凝血酶或A23187诱导的5-羟色胺释放产生剂量依赖性抑制。加入1 mM氯化钙与A23187或凝血酶可部分克服这种抑制作用。在无维拉帕米的情况下加入1 mM氯化钙对凝血酶或A23187诱导的分泌无影响。当以常用剂量给健康志愿者服用维拉帕米时,在药物摄入后2小时观察到血小板聚集受到抑制。有趣的是,维拉帕米在体外可增强前列环素的抗聚集活性。我们的结果可能提示维拉帕米在血栓性疾病治疗中具有潜在作用。